Can Uric Acid Distinguish Lipedema From Overweight?

By
Andrea Surnit
May 29, 2026

Conexiant

Overview

This study investigates the potential of uric acid as a biomarker to differentiate between lipedema, lymphedema, and overweight. While initial findings suggested differences in uric acid levels among these groups, statistical significance was lost after adjusting for various covariates.

Background

Lipedema is a chronic condition characterized by abnormal fat distribution, primarily affecting women, and is often misdiagnosed as obesity or lymphedema. Accurate differentiation is crucial for appropriate management and treatment. Current diagnostic methods lack standardized tests, highlighting the need for reliable biomarkers such as uric acid.

Data Highlights

Group	Median Uric Acid (mg/dL)
Lipedema	5.1
Lymphedema	5.4
Controls	4.6

Key Findings

Uric acid levels were higher in lipedema and lymphedema patients compared to overweight controls.
Median uric acid levels were 5.1 mg/dL in lipedema, 5.4 mg/dL in lymphedema, and 4.6 mg/dL in controls.
The uric acid-to-cystatin c clearance ratio improved discrimination between lipedema and controls (AUC 0.72) and lymphedema and controls (AUC 0.76).
Statistical significance for uric acid levels was lost after adjusting for age, BMI, and renal function.
Lipedema remains a clinical diagnosis without universally accepted diagnostic criteria.
Dietary factors and other causes of altered uric acid metabolism were not accounted for in the study.

Clinical Implications

The findings suggest that while uric acid may show initial promise as a differentiating biomarker, its clinical utility is limited due to loss of significance after adjustment for confounding factors. Clinicians should continue relying on clinical diagnosis and examination for lipedema.

Conclusion

The study indicates that uric acid levels may not be a reliable standalone biomarker for differentiating lipedema from other conditions after accounting for various factors.